Patents matching “anti-”

US 11306149

Anti-CD40 antibodies and uses thereof

CytomX Therapeutics, Inc. · Granted Apr 19, 2022 · Expires Apr 14, 2042

US 11299532

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Apr 12, 2022 · Expires Apr 7, 2042

US 11299553

Anti-plasma kallikrein antibodies

Takeda Pharmaceutical Company Limited · Granted Apr 12, 2022 · Expires Apr 7, 2042

US 11292842

Anti-PD-1 antibodies for treatment of lung cancer

REGENERON PHARMACEUTICALS, INC. · Granted Apr 5, 2022 · Expires Mar 31, 2042

US 11287427

Application of anti-CD39L3 antibodies for use in disease diagnostics and imaging

THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS · Granted Mar 29, 2022 · Expires Mar 24, 2042

US 11286290

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Mar 29, 2022 · Expires Mar 24, 2042

US 11286305

Complex comprising anti-transferrin receptor antibody covalently linked to an oligonucleotide that targets DUX4 RNA

Dyne Therapeutics, Inc. · Granted Mar 29, 2022 · Expires Mar 24, 2042

US 11279768

Anti-cancer antibodies, combination therapies, and uses thereof

PRECISION BIOLOGICS, INC. · Granted Mar 22, 2022 · Expires Mar 17, 2042

US 11274149

Anti-CD100 antibodies and methods for using the same

VACCINEX, INC. · Granted Mar 15, 2022 · Expires Mar 10, 2042

US 11267896

Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof

CytomX Therapeutics, Inc. · Granted Mar 8, 2022 · Expires Mar 3, 2042

US 11267893

Anti-IL36R antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Mar 8, 2022 · Expires Mar 3, 2042

US 11254739

Anti-human migration stimulating factor (MSF) and uses thereof

HUMANITAS MIRASOLE S.P.A. · Granted Feb 22, 2022 · Expires Feb 17, 2042

US 11254752

Methods for treating cancer with bispecific anti-CD3xMUC16 antibodies and anti-PD-1 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Feb 22, 2022 · Expires Feb 17, 2042

US 11254746

Anti-PD-1 monoclonal antibody, and preparation method therefor and application thereof

SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Granted Feb 22, 2022 · Expires Feb 17, 2042

US 11246926

Polynucleotides encoding anti-C1s antibodies

Bioverativ USA Inc. · Granted Feb 15, 2022 · Expires Feb 10, 2042

US 11242339

Chemical inhibition of the E3 ligase subunit FBXO7 confers neuroprotection and anti-inflammatory activity by stabilizing mitochondria

United States Government as represented by the Department of Veterans Affairs · Granted Feb 8, 2022 · Expires Feb 3, 2042

US 11241512

Stabilized radio-labeled anti-CD45 immunoglobulin compositions

Actinium Phamaceuticals, Inc. · Granted Feb 8, 2022 · Expires Feb 3, 2042

US 11235059

Afucosylated anti-FGFR2IIIB antibodies

Five Prime Therapeutics, Inc. · Granted Feb 1, 2022 · Expires Jan 27, 2042

US 11229630

Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs

Olema Pharmaceuticals, Inc. · Granted Jan 25, 2022 · Expires Jan 20, 2042

US 11220535

Anti-BCMA chimeric antigen receptors

Cartesian Therapeutics, Inc. · Granted Jan 11, 2022 · Expires Jan 6, 2042

US 11208456

Anti-KRAS-G12D T cell receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 28, 2021 · Expires Dec 23, 2041

US 11207379

Peptides with anti-cancer activity

IDP DISCOVERY PHARMA, S.L. · Granted Dec 28, 2021 · Expires Dec 23, 2041

US 11207394

Anti-mutated KRAS T cell receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 28, 2021 · Expires Dec 23, 2041

US 11191843

Multi-arm targeting anti-cancer conjugate

BrightGene Bio-Medical Technology Co., Ltd. · Granted Dec 7, 2021 · Expires Dec 2, 2041